Skip to main content

Peripheral neuropathy in children and adolescents treated for cancer.

Publication ,  Journal Article
Bjornard, KL; Gilchrist, LS; Inaba, H; Diouf, B; Hockenberry, MJ; Kadan-Lottick, NS; Bowers, DC; Dolan, ME; Ullrich, NJ; Evans, WE; Ness, KK
Published in: The Lancet. Child & adolescent health
October 2018

Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The Lancet. Child & adolescent health

DOI

EISSN

2352-4650

ISSN

2352-4642

Publication Date

October 2018

Volume

2

Issue

10

Start / End Page

744 / 754

Related Subject Headings

  • Peripheral Nervous System Diseases
  • Neoplasms
  • Humans
  • Child
  • Antineoplastic Agents
  • Adolescent
  • 4206 Public health
  • 3213 Paediatrics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bjornard, K. L., Gilchrist, L. S., Inaba, H., Diouf, B., Hockenberry, M. J., Kadan-Lottick, N. S., … Ness, K. K. (2018). Peripheral neuropathy in children and adolescents treated for cancer. The Lancet. Child & Adolescent Health, 2(10), 744–754. https://doi.org/10.1016/s2352-4642(18)30236-0
Bjornard, Kari L., Laura S. Gilchrist, Hiroto Inaba, Barthelemy Diouf, Marilyn J. Hockenberry, Nina S. Kadan-Lottick, Daniel C. Bowers, et al. “Peripheral neuropathy in children and adolescents treated for cancer.The Lancet. Child & Adolescent Health 2, no. 10 (October 2018): 744–54. https://doi.org/10.1016/s2352-4642(18)30236-0.
Bjornard KL, Gilchrist LS, Inaba H, Diouf B, Hockenberry MJ, Kadan-Lottick NS, et al. Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child & adolescent health. 2018 Oct;2(10):744–54.
Bjornard, Kari L., et al. “Peripheral neuropathy in children and adolescents treated for cancer.The Lancet. Child & Adolescent Health, vol. 2, no. 10, Oct. 2018, pp. 744–54. Epmc, doi:10.1016/s2352-4642(18)30236-0.
Bjornard KL, Gilchrist LS, Inaba H, Diouf B, Hockenberry MJ, Kadan-Lottick NS, Bowers DC, Dolan ME, Ullrich NJ, Evans WE, Ness KK. Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child & adolescent health. 2018 Oct;2(10):744–754.

Published In

The Lancet. Child & adolescent health

DOI

EISSN

2352-4650

ISSN

2352-4642

Publication Date

October 2018

Volume

2

Issue

10

Start / End Page

744 / 754

Related Subject Headings

  • Peripheral Nervous System Diseases
  • Neoplasms
  • Humans
  • Child
  • Antineoplastic Agents
  • Adolescent
  • 4206 Public health
  • 3213 Paediatrics